Discontinuation report DALACIN C 300 MG
| Report ID | 241493 |
| Drug Identification Number | 02182866 |
| Brand name | DALACIN C 300 MG |
| Common or Proper name | DALACIN C 300 MG |
| Company Name | PFIZER CANADA ULC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | CLINDAMYCIN |
| Strength(s) | 300MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | 100 BTL |
| ATC code | J01FF |
| ATC description | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2024-10-29 |
| Remaining supply date | |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
| Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2024-10-29 | English | Compare |
| v2 | 2024-10-29 | French | Compare |
| v3 | 2024-10-30 | English | Compare |
Showing 1 to 3 of 3